Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis

•Meta-analysis of real-world studies on axi-cel vs tisa-cel in rrDLBCL•Axi-cel was associated with significantly improved responses and progression-free survival•Tisa-cel was associated with significantly reduced higher grade CRS and neurotoxicity•Tisa-cel showed significantly reduced utilization of resources